Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy

The standard of care for first-line therapy in diffuse large B-cell lymphoma (DLBCL) is the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen. For patients who fail to respond, have an incomplete response or relapse, numerous effective options exists besides salva...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2017-01, Vol.6 (1), p.122-124
Main Authors: Bowen, Randy C, Hahn, Andrew W, Butler, Thomas W, Khong, Hung T
Format: Article
Language:English
Subjects:
Abdomen
azacitidine
biochemotherapy
Cancer therapies
Care and treatment
Chemotherapy
Clinical trials
Cytotoxicity
Development and progression
Diagnosis
Drug therapy
Health aspects
Lymphoma
Monoclonal antibodies
Mortality
nab-paclitaxel
Neutropenia
non-Hodgkin lymphoma
Non-Hodgkin's lymphomas
Oncology
Paclitaxel
Patient outcomes
Patients
Protein expression
Proteins
Targeted cancer therapy
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The standard of care for first-line therapy in diffuse large B-cell lymphoma (DLBCL) is the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen. For patients who fail to respond, have an incomplete response or relapse, numerous effective options exists besides salvage cisplatin-based regimen and autologous stem cell therapy. Even with this approach, the outcome remains very poor for this group of patients. The present case illustrates a 55-year-old woman diagnosed with DLBCL, who experienced an early incomplete response, later progression during treatment with the R-CHOP regimen. The patient received salvage therapy with rituximab, cisplatin and gemcitabine, again with an incomplete response. The patient declined consideration for stem cell therapy. Her disease progressed and she enrolled in the present phase I trial using azacitadine priming and nanoalbumin-bound (nab)-paclitaxel. After three cycles, follow-up positron emission tomography/computed tomography revealed a complete response for the first time since her initial diagnosis and the patient has remained disease-free for >6 years. Azacitadine and nab-paclitaxel combination appeared to be an effective regimen for the treatment of this patient with refractory DLBCL.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2016.1090